帕克利塔塞尔前期治疗中的H2抗剂:系统性审查和元分析
Mohammed Yahya AlZahrani1,2,3, Maha AlDoughaim4,2,3, Nada AlSuhebany1,2,3
1College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
BMJ supportive & palliative care
|December 9, 2025
概括
在帕克利塔塞尔前期治疗中,不需要使用组胺-2-抗体 (H2As) 来预防过敏反应 (HSR). 省略H2A,就像拉尼蒂丁一样,是安全的,并且不会增加接受帕克利塔塞尔的癌症患者的HSR.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
背景情况:
- 帕克利塔塞尔是一种广泛使用的化疗剂,与过敏反应 (HSR) 相关.
- 立体胺-2 抗剂 (H2As) 经常被纳入前期治疗方案中,以减轻这些反应.
- 在帕克利塔塞尔前期治疗中H2As的必要性和有效性仍然是临床辩论的主题.
研究的目的:
- 系统地审查和分析现有的关于在帕克利塔塞尔前期治疗中使用H2As的文献.
- 确定H2A是否显著降低了帕克利塔塞尔诱导的HSR的发生率.
- 评估从帕克利塔塞尔前期治疗方案中省略H2A的安全性.
主要方法:
- 在MEDLINE,Cochrane和Web of Science数据库中进行了全面的文献搜索,截至2023年12月.
- 包括的研究涉及成人癌症患者接受帕克利塔塞尔输液,并评估了预防性H2As的使用.
- 使用RoBINS-I工具评估偏差风险,并使用随机效应模型进行元分析.
主要成果:
- 六项研究被纳入了元分析.
- 在含有和不含H2As的组之间,在III级或更高级的HSR (RR 1.04,95% CI 0.65-1.67) 或所有级的HSR (RR 1.40,95% CI 0.82-2.39) 的发生率上没有发现统计学上显著的差异.
- 排除前性研究的子组分析显示,所有级别反应的异质性最小.
结论:
- 这些发现支持从帕克利塔塞尔前期治疗方案中安全地省略H2A,特别是ranitidine.
- 遗漏H2A似乎不会影响帕克利塔塞尔诱导的HSR患者的安全.
- 这些证据可以为临床实践指南提供有关帕克利塔塞尔前期治疗的信息.
更多相关视频
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
576
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
576
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
524
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
524
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
790
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
790
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
899
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
899
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
439
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
439
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
857
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
857


